GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
RPG Life Sciences Ltd
RPG Life Sciences Board Approves API Business Sale and Investment Deal
BOARD ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 11:36 PM IST  ·  BSE ID: a31072eb-ee38-4292-b039-a478336503ae
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is selling its API business to its own subsidiary, bringing in new investors for that part of the business.
🤖 AI Summary
  • RPG Life Sciences to sell API business to wholly owned subsidiary RPG Active Pharma.
  • Investment and shareholders' agreement executed with India Life Sciences Fund IV and Vistaject Fund.
  • RPGAP will acquire Actis Generics Private Limited's entire stake.
  • All agreements executed on July 29, 2026, effective immediately.
🏢 How This Affects the Company
📈
Business Impact
This transaction signifies a strategic restructuring of the API business, separating it into a distinct entity with new investment partners.
💰
Financial Impact
The financial implications will depend on the valuation of the slump sale and the terms of the investment agreement. It aims to inject capital into the API segment.
⚙️
Operational Impact
The API business will operate under the subsidiary, RPG Active Pharma Limited, with a new governance structure involving the investors.
⚠️
Risk Impact
New investment partners and a separate operating entity introduce complexities in governance and integration. Regulatory approvals for the share purchase may be a factor.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders concerning this board resolution.
👤
Who Is Affected
All shareholders are indirectly affected by the strategic restructuring of a business segment and the introduction of new investors.
🔍
Management Signal
Management is actively pursuing strategic initiatives to potentially enhance business segment value and attract external capital.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Details of Business Transfer Agreement valuation.
Completion of Actis Generics Private Limited share acquisition.
Announcements regarding regulatory approvals for the transaction.
MEDIUM RISK Transaction involves complex agreements, subsidiary spin-off, and new investor onboarding.
💡 Investor Takeaway
RPG Life Sciences is divesting its API business to a subsidiary, RPG Active Pharma, which will receive investment from India Life Sciences Fund IV and Vistaject Fund.
⚖️ Strengths & Concerns

✅ Positives

  • Strategic move to potentially unlock value in the API business through new investment.
  • Execution of agreements on July 29, 2026, indicates decisive management action.
📅 Company Track Record
Previously, RPG Life Sciences' Board approved a Rs. 24 per share dividend (300% on face value) in April 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is RPG Life Sciences Board's key decision on July 29, 2026?
The Board approved the execution of a Business Transfer Agreement to sell the API business to its wholly owned subsidiary, RPG Active Pharma Limited.
Who are the new investors in RPG Active Pharma Limited?
India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF) are involved in an investment and shareholders' agreement for RPG Active Pharma.
What is being acquired by RPG Active Pharma Limited?
RPGAP will acquire the entire stake of Actis Generics Private Limited as part of this transaction.
What is the basis of the sale of the API business?
The API business is being sold on a slump sale basis as a going concern to RPG Active Pharma Limited.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.